評論
打印
Reuters reports GlaxoSmithKline plans to split into two businesses — one for prescription drugs and vaccines, the other for over-the-counter products.
據(jù)路透社報道，葛蘭素史克公司計劃分拆為兩家公司——一個專注處方藥和疫苗業(yè)務，另一個則專注非處方藥業(yè)務。
This comes after forming a new joint venture with Pfizer's consumer health division.
此前，該公司與輝瑞的消費者健康部門組建了一家新的合資企業(yè)。
The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year.
這是艾瑪·沃爾姆斯利去年出任葛蘭素史克首席執(zhí)行官之后，帶領(lǐng)公司做出的最大膽的改革。
It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent.
這將創(chuàng)造出一家市場份額達到7.3%的消費者健康巨頭，遙遙領(lǐng)先于主要競爭對手強生、拜耳和賽諾菲，它們的市場份額均為4%左右。
譯文屬可可英語原創(chuàng)，未經(jīng)允許，不得轉(zhuǎn)載。
